Are Drug Giants Colluding? U.K. Groups Push for Cartel Probe

A recent wave of concern has rippled through the U.K. health and justice communities. Several advocacy groups are now demanding that the Competition and Markets Authority (CMA) launch an investigation into what they say looks like cartel-style coordination among big pharma players and their industry lobby. The heart of the allegation is that major drug companies and the trade group ABPI (Association of the British Pharmaceutical Industry) may be intentionally timing their investments and public statements to pressure the U.K. government and drive up drug prices.

In a letter dated September 26, groups including Global Justice Now, Just Treatment, and the Balanced Economy Project accused AstraZeneca, Eli Lilly, Merck, and the ABPI of working in concert to withhold or suspend investments in the U.K. over the past year. The letter cites that together these companies paused over £1.5 billion in U.K. projects.

To the signatories, the pattern suggests more than coincidence, it suggests strategic coordination. The groups argue that these actions may amount to behavior intended to extract more favorable pricing or concessions from the government. Reporters have framed these as cartel-like moves.

In particular, the groups point out some recent high-profile pullbacks. Merck reportedly scrapped a £1 billion R&D center and relocated its U.K. headquarters, withdrawing its research operations entirely. AstraZeneca paused a planned investment in its Cambridge research site and canceled another at its Liverpool vaccine facility. Eli Lilly, meanwhile, delayed opening a new lab in the U.K., citing uncertainty about the life sciences investment climate in Britain. All these moves, the advocacy groups say, came at a delicate political moment, sending signals in a calculated fashion.

Opponents argue that using investment as a lever to negotiate pricing or regulatory concessions is an abuse of market power, especially in a sector as critical as medicines. The health groups maintain that if businesses are coordinating their strategies to pressure public health systems, it would be unlawful under the U.K.’s competition laws. The timing and convergence of actions between multiple firms and a trade association raise red flags.

Of course, the companies involved have pushed back, either declining to comment or suggesting their decisions stem from broader strategic reviews, regulatory uncertainty, or unfavorable economics. But observers say that what makes this situation especially sensitive is the essential nature of medicines and the outsized power that pharma firms hold in markets where innovation, patents, and monopoly protections already tilt leverage their way.

If the CMA decides to open a formal probe, it would examine whether these investment pauses and announcements amount to collusive behavior, not just competitive strategy. The stakes are significant: beyond financial penalties, such an investigation could reshape the way drugmakers interact with national health systems, contract pricing, and public investments in R&D.

What seems clear is that for those campaigning for transparency and fairness, this isn’t just about a few delayed factories or halted labs. It’s about ensuring that the public doesn’t pay a hidden cost when companies treat investment decisions as bargaining chips. Whether this becomes a full-blown legal showdown or fades amid industry pushback, it highlights a deeper tension in pharma — the balance between market strategy and public accountability in something as vital as medicine access.

G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com